WO2008099906A1 - 歯周病、及び外科手術による歯槽骨欠損の治療剤 - Google Patents

歯周病、及び外科手術による歯槽骨欠損の治療剤 Download PDF

Info

Publication number
WO2008099906A1
WO2008099906A1 PCT/JP2008/052482 JP2008052482W WO2008099906A1 WO 2008099906 A1 WO2008099906 A1 WO 2008099906A1 JP 2008052482 W JP2008052482 W JP 2008052482W WO 2008099906 A1 WO2008099906 A1 WO 2008099906A1
Authority
WO
WIPO (PCT)
Prior art keywords
periodontal disease
alveolar bone
loss due
surgery
bone loss
Prior art date
Application number
PCT/JP2008/052482
Other languages
English (en)
French (fr)
Inventor
Ryuichi Morishita
Hironori Nakagami
Hideo Shimizu
Original Assignee
Anges Mg, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg, Inc. filed Critical Anges Mg, Inc.
Priority to JP2008558139A priority Critical patent/JP5384120B2/ja
Priority to US12/449,522 priority patent/US20100105762A1/en
Priority to EP08711312A priority patent/EP2127681A4/en
Publication of WO2008099906A1 publication Critical patent/WO2008099906A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

　本発明により、ＮＦκＢによる転写活性化を抑制することにより、歯周病モデルにおいて歯槽骨の吸収が抑制され、歯周病骨欠損モデルにおいて歯槽骨の修復を促進されることが明らかとなった。そこで、本発明は、ＮＦκＢデコイ等のＮＦκＢの転写活性を抑制する有効成分を含有する歯周病、及び外科手術等による歯槽骨欠損の治療、予防、及び改善剤を提供するものである。
PCT/JP2008/052482 2007-02-16 2008-02-15 歯周病、及び外科手術による歯槽骨欠損の治療剤 WO2008099906A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2008558139A JP5384120B2 (ja) 2007-02-16 2008-02-15 歯周病、及び外科手術による歯槽骨欠損の治療剤
US12/449,522 US20100105762A1 (en) 2007-02-16 2008-02-15 Therapeutic agent for periodontal disease and alveolar bone loss due to surgery
EP08711312A EP2127681A4 (en) 2007-02-16 2008-02-15 THERAPEUTIC AGENT AGAINST PARODONTAL DISEASES AND ALVEOLAR BONE LOSS THROUGH OPERATION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-036135 2007-02-16
JP2007036135 2007-02-16

Publications (1)

Publication Number Publication Date
WO2008099906A1 true WO2008099906A1 (ja) 2008-08-21

Family

ID=39690131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052482 WO2008099906A1 (ja) 2007-02-16 2008-02-15 歯周病、及び外科手術による歯槽骨欠損の治療剤

Country Status (4)

Country Link
US (1) US20100105762A1 (ja)
EP (1) EP2127681A4 (ja)
JP (1) JP5384120B2 (ja)
WO (1) WO2008099906A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082600A1 (ja) * 2009-01-15 2010-07-22 サンスター株式会社 オレウロペインおよびその分解物を含有する歯周組織健康維持剤

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006064886A1 (ja) * 2004-12-16 2008-06-12 アンジェスＭｇ株式会社 骨形成調節剤
EP3245290A4 (en) * 2015-01-16 2018-11-07 University of Iowa Research Foundation Methods to prevent or treat periodontitis or peri-implantitis
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3392143A (en) 1967-05-15 1968-07-09 Gen Electric Polyamide compositions
WO1995011687A1 (en) 1993-10-29 1995-05-04 Dzau Victor J Therapeutic use of cis-element decoys in vivo
WO1996035430A1 (fr) 1995-05-12 1996-11-14 Fujisawa Pharmaceutical Co., Ltd. TRAITEMENT ET PREVENTION DE MALADIES ASSOCIEES A NF-λB
WO2002066070A1 (fr) 2001-02-20 2002-08-29 Anges Mg, Inc. Compositions pharmaceutiques contenant un leurre et procede d'utilisation associe
WO2003000297A1 (fr) * 2001-06-20 2003-01-03 Sumitomo Pharmaceuticals Company, Limited Procede facilitant le transfert d'acides nucleiques
WO2003043663A1 (fr) 2001-11-22 2003-05-30 Anges Mg, Inc. Preparations inhibant le rejet dans la transplantation d'organe et son procede d'utilisation
WO2003063911A1 (fr) 2002-02-01 2003-08-07 Anges Mg, Inc. Compositions pharmaceutiques contenant un leurre et procede d'utilisation
WO2003082331A1 (fr) 2002-03-29 2003-10-09 Anges Mg, Inc. Compositions de leurre destinees au traitement et a la prevention de maladies et de pathologies cerebrales
WO2003099339A1 (fr) 2002-05-29 2003-12-04 Anges Mg, Inc. Composition leurre pour traiter et prevenir une affection inflammatoire
WO2004026342A1 (ja) 2002-09-20 2004-04-01 Anges Mg, Inc. NFκBデコイを含有する移植片新生内膜肥厚に対する保護剤
WO2005004913A1 (ja) 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
WO2005056020A2 (en) * 2003-12-02 2005-06-23 Corgentech, Inc. Nf-kb oligonucleotide decoy molecules
JP2005160464A (ja) 2003-12-02 2005-06-23 Corgentech Inc ＮＦ−κＢオリゴヌクレオチドデコイ分子
WO2006064886A1 (ja) 2004-12-16 2006-06-22 Anges Mg, Inc. 骨形成調節剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354557A (en) * 1988-04-08 1994-10-11 Stryker Corporation Osteogenic devices
US6462019B1 (en) * 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US7615373B2 (en) * 1999-02-25 2009-11-10 Virginia Commonwealth University Intellectual Property Foundation Electroprocessed collagen and tissue engineering
US8158685B2 (en) * 2004-07-02 2012-04-17 Gregory Gene Steiner Method for bone growth

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3392143A (en) 1967-05-15 1968-07-09 Gen Electric Polyamide compositions
WO1995011687A1 (en) 1993-10-29 1995-05-04 Dzau Victor J Therapeutic use of cis-element decoys in vivo
WO1996035430A1 (fr) 1995-05-12 1996-11-14 Fujisawa Pharmaceutical Co., Ltd. TRAITEMENT ET PREVENTION DE MALADIES ASSOCIEES A NF-λB
WO2002066070A1 (fr) 2001-02-20 2002-08-29 Anges Mg, Inc. Compositions pharmaceutiques contenant un leurre et procede d'utilisation associe
WO2003000297A1 (fr) * 2001-06-20 2003-01-03 Sumitomo Pharmaceuticals Company, Limited Procede facilitant le transfert d'acides nucleiques
WO2003043663A1 (fr) 2001-11-22 2003-05-30 Anges Mg, Inc. Preparations inhibant le rejet dans la transplantation d'organe et son procede d'utilisation
WO2003063911A1 (fr) 2002-02-01 2003-08-07 Anges Mg, Inc. Compositions pharmaceutiques contenant un leurre et procede d'utilisation
WO2003082331A1 (fr) 2002-03-29 2003-10-09 Anges Mg, Inc. Compositions de leurre destinees au traitement et a la prevention de maladies et de pathologies cerebrales
WO2003099339A1 (fr) 2002-05-29 2003-12-04 Anges Mg, Inc. Composition leurre pour traiter et prevenir une affection inflammatoire
WO2004026342A1 (ja) 2002-09-20 2004-04-01 Anges Mg, Inc. NFκBデコイを含有する移植片新生内膜肥厚に対する保護剤
WO2005004913A1 (ja) 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
WO2005004914A1 (ja) 2003-07-09 2005-01-20 Anges Mg, Inc. NF-κBデコイを含む呼吸器疾患用治療および予防のための薬学的組成物およびその使用方法
WO2005056020A2 (en) * 2003-12-02 2005-06-23 Corgentech, Inc. Nf-kb oligonucleotide decoy molecules
JP2005160464A (ja) 2003-12-02 2005-06-23 Corgentech Inc ＮＦ−κＢオリゴヌクレオチドデコイ分子
WO2006064886A1 (ja) 2004-12-16 2006-06-22 Anges Mg, Inc. 骨形成調節剤

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Bunshi Saibou Seibutugaku Jiten", 1997, TOKYO KAGAKU DOJIN, pages: 891
AM J CHEM SOC, vol. 103, 1981, pages 3185 - 3191
AMBILI R. ET AL.: "Expression of activated transcription factor nuclear factor-kappa B in periodontally diseased tissues", J. PERIODONTOL., vol. 76, no. 7, 2005, pages 1148 - 1153, XP008113877 *
ANN REV IMMUNOL, vol. 14, 1996, pages 649 - 683
CELL, vol. 46, 1986, pages 705 - 716
FEBS LETTERS, vol. 580, 2006, pages 613 - 619
FOSTER N. ET AL.: "VIP inhibits porphyromonas gingivalis LPS-induced immune responses in human monocytes", J. DENT. RES., vol. 84, no. 11, 2005, pages 999 - 1004, XP008113868 *
IMMUNOL TODAY, vol. 19, 1998, pages 80 - 88
J. PERIODONT. RES., vol. 38, 2003, pages 97 - 103
J. PERIODONTOL, vol. 76, 2005, pages 1148 - 1153
JOURNAL OF THE JAPANESE SOCIETY OF PERIODONTOLOGY, vol. 36, no. 4, 1994, pages 823 - 833
NAT REV CANCER, vol. 2, 2002, pages 301 - 310
NATURE, vol. 310, 1984, pages 105 - 111
TRENDS MOL MED, vol. 8, 2002, pages 385 - 389

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082600A1 (ja) * 2009-01-15 2010-07-22 サンスター株式会社 オレウロペインおよびその分解物を含有する歯周組織健康維持剤
JPWO2010082600A1 (ja) * 2009-01-15 2012-07-05 サンスター株式会社 オレウロペインおよびその分解物を含有する歯周組織健康維持剤
JP2015071623A (ja) * 2009-01-15 2015-04-16 サンスター株式会社 オレウロペインおよびその分解物を含有する歯周組織健康維持剤

Also Published As

Publication number Publication date
JPWO2008099906A1 (ja) 2010-05-27
EP2127681A1 (en) 2009-12-02
US20100105762A1 (en) 2010-04-29
JP5384120B2 (ja) 2014-01-08
EP2127681A4 (en) 2011-10-12

Similar Documents

Publication Publication Date Title
WO2009074735A3 (fr) Utilisation d'un nouvel agent naturel dans des compositions cosmetiques
WO2009101503A3 (fr) Utilisation de substances actives naturelles dans des compositions cosmétiques ou thérapeutiques
WO2010111640A3 (en) Anti-influenza formulations and methods
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2007087431A3 (en) Sublingual fentanyl spray
WO2009017837A3 (en) Sublingual fentanyl spray
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2011017483A8 (en) Sublingual and buccal film compositions
WO2010048087A3 (en) Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
WO2006052451A3 (en) Implantable collagen compositions
EP1774968A4 (en) BENZYLISOQUINOLEIN DERIVATIVE OR BISBENZYLISOQUINOLEIN DERIVATIVE - CONTAINING PSYCHOTROPIC, ANALGESIC AND / OR ANTIPHLOGISTIC AGENT, AND HEALTH FOOD.
WO2008070670A3 (en) Enhanced immediate release formulations of topiramate
EP2889027A3 (en) Oral preparation, injection preparation, external skin preparation and cosmetic method for preventing or improving wrinkles
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
WO2009022077A3 (fr) Utilisation d'hespéridine ou de l'un de ses dérivés pour la prévention et/ou le traitement des peaux relâchées
WO2010106008A3 (en) Fungicidal compositions comprising fluopyram and metrafenone
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2007123740A3 (en) Pharmaceutical compositions for promoting wound healing
WO2009051223A1 (ja) 白内障処置のための医薬組成物
WO2007079312A3 (en) Compositions and methods for treating actin-mediated medical conditions
WO2008099906A1 (ja) 歯周病、及び外科手術による歯槽骨欠損の治療剤
EP2801360A3 (en) The use of nicotine for the treatment of post traumatic bleeding in humans

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711312

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008558139

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008711312

Country of ref document: EP